Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 479-498 , September 2007

Chemoimmunotherapy of chronic lymphocytic leukemia

References 

  1. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. Journal of the National Cancer Institute. 1999;91:861–868
  2. Call TG, Phyliky RL, Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clinic Proceedings. Mayo Clinic. 1994;69:323–328
  3. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165–1171
  4. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 2002;119:976–984
  5. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005;23:4079–4088
  6. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005;23:4070–4078
  7. Wierda W, O'Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006;106:337–345
  8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  9. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29–35
  10. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology. 2005;23:2971–2979
  11. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19–25
  12. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. The New England Journal of Medicine. 2000;343:1750–1757
  13. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432–1438
  14. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319–2325
  15. Catovsky D, Richards S, Hillmen P. Early results from LRF CLL4: a UK multicenter randomized trial. Blood. 2005;11:212a;(abstract 716)
  16. Koehi U, Ying Yang L, Nowak B, et al. Effect of combined treatment with 4-hydroperoxycyclophosphamide and fludarabine on cytotoxicity and repair of damaged DNA. Acute Leukemias VII: Experimental Approaches and Novel Therapies. Berlin: Springer-Verlag; 1998;549–555
  17. Robertson LE, O'Brien S, Kantarjian H, et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995;9:943–945
  18. Rummel MJ, Kafer G, Pfreundschuh M, et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Annals of Oncology. 1999;10:183–188
  19. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology. 2001;19:1414–1420
  20. Tsimberidou AM, Keating MJ, Giles FJ, et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004;100:2583–2591
  21. Tam CS, Wolf MM, Januszewicz EH, et al. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer. 2004;100:2181–2189
  22. Gonzalez H, Cazin B, Dighiero G, et al. Fludarabine (FAMP) and cyclophosphamide (CTX) combination in chronic lymphocytic leukemia (CLL). Blood. 1998;2776b;(abstract 4193)
  23. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. British Journal of Haematology. 2001;114:342–348
  24. Schiavone EM, De Simone M, Palmieri S, et al. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. European Journal of Haematology. 2003;71:23–28
  25. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71–75
  26. Cazin B, Maloum K, Divine M, et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 59 patients. Blood. 2001;98(supplement):772a;(abstract 3214)
  27. Kawai Y, Plunkett W. DNA repair induced by 4-hydroperxycyclophosphamide permits fludarabine nucleotide incorporation and is associated with synergistic induction of apoptosis in quiescent human lymphocytes. Blood. 1999;94(supplement):655a;(abstract 2910)
  28. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891
  29. Flinn I, Kumm E, Grever M, et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. Blood. 2004;104(11):139a;(abstract 475)
  30. Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Annals of Oncology. 2001;12:1455–1460
  31. Elias L, Stock-Novack D, Head DR, et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia. 1993;7:361–365
  32. Schmitt B, Franke A, Schlag R, et al. Fludarabine plus cyclophosphamide and mitoxantrone (FCM) in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Leukemia and Lymphoma. 2004;44(supplement 2):S45;(abstract 83)
  33. Mauro FR, Foa R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 2002;87:926–933
  34. Bosch F, Ferrer A, Villamor N, et al. Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL. ASH Annual Meeting Abstracts. 2005;106:718
  35. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology. 2003;21:1278–1284
  36. Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108:473–479
  37. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:1755–1762
  38. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94:2033–2039
  39. Zhou LJ, Tedder TF. CD20 Workship Panel Report. In:  Schlossman SF,  Boumsell L,  Gilks W,  Harlan JM,  Kishimoto T,  Morimoto C,  Ritz J,  Shaw S,  Silverstein R editor. Leucocyte Typing V White Cell Differentiation Antigens. Oxford: Oxford University; 1995;p. 511–514
  40. Voso MT, Pantel G, Rutella S, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica. 2002;87:918–925
  41. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology. 1998;16:2825–2833
  42. Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. European Journal of Haematology. 2002;69:129–134
  43. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326–1331
  44. Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. American Journal of Hematology. 1992;40:259–263
  45. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513
  46. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology. 2001;19:2165–2170
  47. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 2003;21:1746–1751
  48. Thomas DA, O'Brien S, Giles F, et al. Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL). Blood. 2001;98:364a;(abstract 1533)
  49. Venugopal P, Sivaraman S, Huang XK, et al. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leukemia Research. 2000;24:411–415
  50. Ferrajoli A, O'Brien S, Faderl S, et al. Rituximab plus GM-CSF for Patients with Chronic Lymphocytic Leukemia. Blood. 2005;106:214a;(abstract 721)
  51. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807–812
  52. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology. 1996;93:151–153
  53. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 1997;15:1567–1574
  54. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  55. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology. 2002;20:3891–3897
  56. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773–778
  57. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768–773
  58. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004;104:948–955
  59. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002;87:695–700
  60. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657–2663
  61. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093–1101
  62. Rai KR, Byrd J, Peterson B, Larson RA. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901. Blood. 2002;100:(abstract 772)
  63. Rai K, Byrd J, Peterson B, et al. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemie (CLL): CALGB Study 19901. Blood. 2003;102:(abstract 2506)
  64. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413–3415
  65. Faderl S, Ferrajoli A, Wierda W, et al. Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2005;106:2963
  66. Byrd JC, O'Brien S, Flinn I, et al. Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2004;104:2503
  67. Crawford DH, Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology. 1993;80:40–44
  68. Tong X, Georgakis GV, Li L, et al. In Vitro Activity of a Novel Fully Human Anti-CD40 Antibody CHIR-12.12 in Chronic Lymphocytic Leukemia: Blockade of CD40 Activation and Induction of ADCC. ASH Annual Meeting Abstracts. 2004;104:2504
  69. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106:3348–3352
  70. Chanan-Khan A, Miller K, DiMiceli L, et al. Results of Phase II Study of Lenalidomide (Revlimid) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 2005;106:135a;(abstract 447)
  71. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clinical Cancer Research. 2001;7:709–723
  72. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica. 2002;87:33–43
  73. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. British Journal of Haematology. 2001;114:800–809
  74. Tam CS, Wolf MM, Prince HM, et al. Fludarabine, Cyclophosphamide and Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukaemia or Indolent Non-Hodgkin Lymphoma Cancer. Cancer. 2006;106:2412–2420
  75. Keating MJ, O'Brien S, Lerner S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves complete response, remission duration and survival as initial therapy of Chronic Lymphocytic Leukemia (CLL). Proceedings of the American Society of Clinical Oncology. 2004;23:(abstract 6565)
  76. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology. 2001;19:2153–2164
  77. O'Brien S, Wierda WG, Faderl S, et al. FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2005;106:2117
  78. Faderl S, Wierda W, O'Brien S, et al. A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL <= 70 years (yrs). Journal of Clinical Oncology Meeting Abstracts. 2006;24:6607
  79. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14
  80. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53
  81. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115–3120
  82. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostain, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405–411
  83. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology. 2006;24:1575–1581
  84. Yunus F, George S, Smith J, et al. Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia. Blood. 2003;102:(abstracts 5168)
  85. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245–2247
  86. Sayala H, Moreton P, Richard JA, et al. Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). ASH Annual Meeting Abstracts. 2005;106:2120
  87. Elter T, Borshmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology. 2005;23:7024–7031
  88. Catovsky D, Richards S, Matutes E, et al. Response to Therapy and Survival in CLL is influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial. Blood. 2004;104;(abstract 13)
  89. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278–3281
  90. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Annals of Hematology. 2003;82:759–765
  91. el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993;82:3452–3459
  92. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580–1589
  93. Wierda W, O'Brien S, Ferrajoli A, et al. Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. Blood. 2005;106:213a;(abstract 719)
  94. Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 2006;108:4187–4193
  95. Wierda W, Tsimberidou A, O'Brien S, et al. The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's Transformation and FLU-refractory CLL. Jounal of Clinical Oncology Meeting Abstracts. 2006;24:6608
  96. Kipps TJ. Immune and cell therapy of hematologic malignancies. International Journal of Hematology. 2002;76(supplement 1):269–273
  97. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology. 2004;32:28–35

PII: S1521-6926(07)00020-5

doi: 10.1016/j.beha.2007.02.004

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 479-498 , September 2007

Article Tools

* Image Usage & Resolution